✦ LIBER ✦

Hypothesis: How do JAK2-inhibitors work in myelofibrosis

✍ Scribed by Ruben Mesa; Robert Peter Gale

Book ID: 104041064
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 205 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2009.04.011

No coin nor oath required. For personal study only.

✦ Synopsis

JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather than the abnormal clones.

📜 SIMILAR VOLUMES

How many JAK inhibitors in myelofibrosis

How many JAK inhibitors in myelofibrosis?

✍ Ferreira, Bruna Velosa; Harrison, Claire 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 247 KB

Ruxolitinib, an oral JAK1 and JAK2 inhib

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

✍ Vaddi, Kris; Sarlis, Nicholas J; Gupta, Vikas 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 545 KB

Safety and Efficacy of INCB018424, a JAK

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

✍ Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cor 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 542 KB

Safety and efficacy of CYT387, a JAK1 an

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

✍ Pardanani, A; Laborde, R R; Lasho, T L; Finke, C; Begna, K; Al-Kali, A; Hogan, W 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 510 KB

Allogeneic hematopoietic cell transplant

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

✍ Jaekel, N; Behre, G; Behning, A; Wickenhauser, C; Lange, T; Niederwieser, D; Al- 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB

Evaluating the serial use of the myelofi

Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement : Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial

✍ Ruben A. Mesa; Hagop Kantarjian; Ayalew Tefferi; Amylou Dueck; Richard Levy; Kri 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB 👁 1 views

## Abstract ## BACKGROUND: Symptomatic burden from constitutional symptoms, anemia, and splenomegaly‐related symptoms are common and morbidity inducing in patients with myelofibrosis (MF). The authors previously developed a MF‐specific instrument for capturing the burden of MF‐associated disease‐r